A new real-world study from the Cleveland Clinic suggests popular GLP-1 weight-loss medications might slow how some obesity-related cancers spread, with notable reductions in progression for lung, breast, colorectal and liver cancers; researchers warn the analysis is retrospective and more trials are needed to confirm whether the drugs are doing the protecting or if other factors are at play.
Researchers evaluated 12,112 patients diagnosed with obesity-associated cancers at stages 1 through 3, tracking outcomes after treatment choices made post-diagnosis. Roughly half of the group began treatment with a GLP-1 agent such as semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide, while the other half took DPP-4 inhibitors, often called gliptins.
The headline result was a lower rate of progression to stage 4 disease among GLP-1 users for four tumor types. The largest drops were seen in non-small cell lung cancer, where progression was cut by about half, followed by breast cancer at 43 percent, colorectal cancer at 31 percent and liver cancer at 38 percent.
Three additional cancers—prostate, pancreatic and kidney—showed lower spread rates in GLP-1 users too, but those differences did not meet statistical significance. That caveat matters because without statistical significance the results could reflect chance or differences in how the patient groups were selected and treated.
Investigators also looked at tumor biology and found that cancers with higher levels of GLP-1 receptors tended to do better. Across the study population, patients whose tumors expressed more of these receptors were about one-third less likely to die during the observation window, suggesting a possible biological link worth studying further.
Safety signals in this comparison were reassuring: adverse side effects occurred at similar rates between the GLP-1 group and the gliptin group. That detail doesn’t settle long-term safety questions, but it does reduce the likelihood that simple toxicity differences explain the survival patterns observed here.
“Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,” said lead study author Mark David Orland, MD, of the Taussig Cancer Institute at Cleveland Clinic, in the release. “It provides early evidence that future studies are worth pursuing.”
The team stresses important limitations. This was a retrospective, observational analysis rather than a randomized clinical trial, so it cannot prove GLP-1 drugs prevented progression. Other variables—patients’ underlying health, the degree of weight loss they achieved, metabolic improvements, or differences in cancer treatment—could all have influenced outcomes.
Because some cancer subgroups were small, the study may have been underpowered to detect real benefits in a few tumor types, and the findings have not yet undergone peer review. Researchers are calling for randomized clinical trials to test whether GLP-1 pathways directly alter tumor growth and spread, and to pin down mechanisms if a true protective effect exists.
